Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pediatric Chronic Myeloid Leukemia Registry (PCMLR)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by Poitiers University Hospital.
Recruitment status was  Recruiting
Institut National de la Santé Et de la Recherche Médicale, France
University of Milano Bicocca
University Medical Center Groningen
University Hospital of Liege
Imperial College London
University Hospital Dresden
International BFM Study Group
Information provided by:
Poitiers University Hospital Identifier:
First received: January 14, 2011
Last updated: February 7, 2011
Last verified: February 2011
The purpose of the study is to describe and characterize CML in a large pediatric cohort of patients.

Chronic Myeloid Leukemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: INTERNATIONAL STUDY of Chronic Myeloid Leukaemia (CML) Treatment and Outcomes in Children and Adolescents

Resource links provided by NLM:

Further study details as provided by Poitiers University Hospital:

Estimated Enrollment: 750
Study Start Date: January 2011
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients less than 18 years of age with newly diagnosed Philadelphia positive and/or bcr-abl positive CML are eligible whatever the phase of the disease, the type of treatment and the enrollment or not in a clinical study.

Inclusion Criteria:

  • patients less than 18 years of age
  • diagnosed Philadelphia positive and/or BCR-ABL positive Chronic Myeloid Leukemia (CML) all phases

Exclusion Criteria:

  • patients more than 18 years of age at diagnosis of CML
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01281735

Contact: Frederic MILLOT, MD +33 (0)5 49 44 30 78

  Hide Study Locations
Hospital Italiano Recruiting
Buenos Aires, Argentina
Contact: Eduardo DIBAR, Prof.   
Principal Investigator: Eduardo DIBAR, MD         
Australia, South Australia
Women's and children's Hospital Recruiting
North Adelaide, South Australia, Australia, 5006
Contact: Heather TAPP, Prof.   
Principal Investigator: Heather TAPP, MD         
Children's Cancer Research Institute Recruiting
Vienna, Austria, 1090
Contact: Mchael DWORZAK, Prof.   
Principal Investigator: Michael DWORZAK, MD         
National Research Center for Pediatric Oncology and Hematology Recruiting
Minsk, Belarus
Contact: Natalia SAVVA, MD   
Principal Investigator: Natalia SAVVA, MD         
University of Liege Recruiting
Liege, Belgium, 4000
Contact: Marie Françoise DRESSE, Prof.   
Principal Investigator: Marie Françoise DRESSE, MD         
Instituto de Oncologia Pediatrica Recruiting
Sao Paulo, Brazil, 04023-062
Contact: Maria Lucia LEE, MD   
Principal Investigator: Maria Lucia LEE, MD         
Hospital Roberto Del Rio Recruiting
Santiago, Chile
Contact: Myriam CAMPBELL BULL, MD   
Principal Investigator: Myriam CAMPBELL BULL, MD         
Chinese University of Hong Kong Recruiting
Hong Kong, China
Contact: Li CHI KONG, Prof.   
Principal Investigator: Li CHI KONG, MD         
Rigshospitalet Recruiting
Copenhagen, Denmark, 2100
Contact: Birgitte LAUSEN, MD    45 3545 8177   
Principal Investigator: Birgitte LAUSEN, MD         
Clinical Investigation Center CIC 0802 Recruiting
Poitiers, France, 86021
Contact: Sophie ZIN-KA-IEU, PhD    +33 (0)5 49 44 30 57   
Contact: Joelle GUILHOT, MSc    +33 (0)5 49 44 46 89   
Principal Investigator: Frederic MILLOT, MD         
University Hospital Dresden Recruiting
Dresden, Germany, 01307
Contact: Meinolf SUTTORP, Prof.   
Principal Investigator: Meinolf SUTTORP, MD         
Agia Sophia Children's Hospital Recruiting
Athen, Greece, 11527
Contact: Vassilios PAPADAKIS, MD   
Principal Investigator: Vassilios PAPADAKIS, MD         
University of Milano-Bicocca Recruiting
Milano, Italy, 20126
Contact: Andrea BIONDI, MD   
Principal Investigator: Andrea BIONDI, MD         
Keio University School of Medicine Recruiting
Tokyo, Japan, 160-8582
Contact: Shimada HIROYUKI, MD PhD   
Principal Investigator: Shimada HIROYUKI, MD PhD         
University Medical Centre Groningen Recruiting
Groningen, Netherlands, 9700 AB
Contact: Eveline DE BONT, Prof.   
Principal Investigator: Eveline DE BONT, MD         
Faculty of Medicine Recruiting
Bratislava, Slovakia, 813 72
Contact: Emilia KAISEROVA, Prof   
Principal Investigator: Emilia KAISEROVA, MD         
United Kingdom
Imperial college Healthcare Recruiting
London, United Kingdom, W2
Principal Investigator: Josu DE LA FUENTE, MD         
Sponsors and Collaborators
Poitiers University Hospital
Institut National de la Santé Et de la Recherche Médicale, France
University of Milano Bicocca
University Medical Center Groningen
University Hospital of Liege
Imperial College London
University Hospital Dresden
International BFM Study Group
Principal Investigator: Frederic MILLOT, MD Poitiers University Hospital
  More Information

Responsible Party: MILLOT, Clinical investigation center CIC 0802 Identifier: NCT01281735     History of Changes
Other Study ID Numbers: CIC09-33  2010-023359-27 
Study First Received: January 14, 2011
Last Updated: February 7, 2011
Health Authority: France: French Data Protection Authority

Keywords provided by Poitiers University Hospital:
treatment outcome
side effects
Protein Kinase Inhibitors

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases processed this record on October 25, 2016